CHRONIC NEUROPATHIC PAIN MECHANISMS AND MANAGEMENT
慢性神经病理性疼痛的机制和治疗
基本信息
- 批准号:6639330
- 负责人:
- 金额:$ 11.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-06-28 至 2005-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted From The Applicant's Abstract): Michael Rowbotham, a
clinical neurologist and clinical neuroscientist specializing in chronic pain,
has an international reputation as a leader in patient-oriented research on
neuropathic pain mechanisms and clinical analgesic trials. The UCSF Pain
Clinical Research Center (PCRC), started by Dr. Rowbotham in 1990, is a
clinical research unit located in University-owned space that receives NIH,
private, and industry support for exploratory clinical research and clinical
trials. As a PI in the NINDS Program Project on Pain Mechanisms at UCSF,
clinical research that translates advances from the Program's four basic
science labs is fostered. Dr. Rowbotham has mentored 15 beginning clinical
scientists from diverse backgrounds in the PCRC, and is developing a unique two
year research/clinical training program that brings together the PCRC, the
Neurology Pain Research Training Grant, and the Anesthesia-Pain Management
Center Fellowship. K-24 support for a 5 year period will assist Dr. Rowbotham
achieve his long-term career goal of establishing an integrated clinical
research program that: (1) has a comprehensive pain research training
curriculum for beginning clinical investigators; (2) conducts exploratory
clinical research on pain mechanisms underlying different neuropathic pain
disorders; (3) uses experimental pain models to evaluate new analgesics in
healthy volunteers and patients, (4) translates basic science advances into
well designed clinical trials to advance pain therapy; (5) relates pain
mechanisms to opioid sensitivity, tolerance, and long term efficacy. The
experiments in Project I will: (a) determine if opioid-insensitive chronic
pains exist by simultaneously measuring the response of experimentally induced
pain and ongoing clinical pain to i.v. remifentanil infusion; (b) determine if
a prolonged i.v. remifentanil infusion can produce acute analgesic tolerance to
both the experimentally induced pain and hyperalgesia and the ongoing chronic
pain; and (c) prospectively assess development of opioid analgesic tolerance
during long term oral opioid therapy. Project II will test the hypothesis that
development of chronic post-herpetic neuralgia after herpes zoster strongly
depends on the severity of the initial neural injury and the quality of neural
recovery. Patients with acute zoster pain will be followed for 6 months on
measures of pain intensity, mood, quality of life, allodynia, extent of
affected skin, quantitative tests of sensory function, response to controlled
applications of capsaicin, and serial skin punch biopsy measurement of
cutaneous innervation in affected and normal skin.
描述(改编自申请者摘要):Michael Rowbotham,a
临床神经学家和专门研究慢性疼痛的临床神经学家,
在以病人为中心的研究方面享有国际声誉
神经病理性疼痛机制及临床止痛试验。加州大学旧金山分校的疼痛
临床研究中心(PCRC)由罗伯坦博士于1990年创立,是一家
临床研究单位位于大学拥有的空间内,接待NIH,
为探索性临床研究和临床提供私人和行业支持
审判。作为加州大学旧金山分校疼痛机制NINDS项目的PI,
将该计划的四个基本内容的进展转化为临床研究
科学实验室得到了培育。Rowbotham医生指导了15名临床初学者
来自不同背景的科学家在PCRC,并正在开发一种独特的两种
年研究/临床培训计划,将PCRC、
神经学疼痛研究培训助学金与麻醉-疼痛管理
中心联谊会。为期5年的K-24支持将协助罗伯坦博士
实现他长期的职业目标,建立一个综合的临床
研究计划:(1)有全面的疼痛研究培训
初级临床研究人员的课程;(2)进行探索性
不同神经病理性疼痛机制的临床研究
紊乱;(3)使用实验性疼痛模型评估新的止痛药
健康志愿者和患者,(4)将基础科学进步转化为
精心设计的促进疼痛治疗的临床试验;(5)与疼痛有关
阿片类药物敏感性、耐受性和长期疗效的机制。这个
项目I中的实验将:(A)确定阿片类药物不敏感的慢性
痛苦是通过同时测量实验诱导的
疼痛和持续的临床疼痛静脉注射。瑞芬太尼输注;(B)确定
长时间的静脉注射。瑞芬太尼输注可产生急性止痛耐受
实验诱导的疼痛和痛觉过敏以及正在进行的慢性
以及(C)前瞻性评估阿片类止痛剂耐受性的发展。
在长期口服阿片类药物治疗期间。项目II将检验假设
强直性带状疱疹后慢性带状疱疹后遗神经痛的发生
取决于初始神经损伤的严重程度和神经的质量
恢复。对患有急性带状疱疹疼痛的患者进行为期6个月的随访
疼痛强度、情绪、生活质量、痛觉异常、疼痛程度的测量
受影响的皮肤,感觉功能的定量测试,对受控的反应
辣椒素的应用和连续皮肤穿孔活检测量
病变皮肤和正常皮肤的皮肤神经支配。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL C ROWBOTHAM其他文献
MICHAEL C ROWBOTHAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL C ROWBOTHAM', 18)}}的其他基金
Opioid Responsivity/ Analgesic Tolerance in Chronic Pain
慢性疼痛中的阿片类药物反应/镇痛耐受性
- 批准号:
6565208 - 财政年份:2002
- 资助金额:
$ 11.72万 - 项目类别:
Opioid Responsivity/ Analgesic Tolerance in Chronic Pain
慢性疼痛中的阿片类药物反应/镇痛耐受性
- 批准号:
6411534 - 财政年份:2001
- 资助金额:
$ 11.72万 - 项目类别:
CHRONIC NEUROPATHIC PAIN MECHANISMS AND MANAGEMENT
慢性神经病理性疼痛的机制和治疗
- 批准号:
6539502 - 财政年份:2000
- 资助金额:
$ 11.72万 - 项目类别:
CHRONIC NEUROPATHIC PAIN MECHANISMS AND MANAGEMENT
慢性神经病理性疼痛的机制和治疗
- 批准号:
6393191 - 财政年份:2000
- 资助金额:
$ 11.72万 - 项目类别:
CHRONIC NEUROPATHIC PAIN MECHANISMS AND MANAGEMENT
慢性神经病理性疼痛的机制和治疗
- 批准号:
6088141 - 财政年份:2000
- 资助金额:
$ 11.72万 - 项目类别:
Opioid Responsivity/ Analgesic Tolerance in Chronic Pain
慢性疼痛中的阿片类药物反应/镇痛耐受性
- 批准号:
6302765 - 财政年份:2000
- 资助金额:
$ 11.72万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 11.72万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 11.72万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 11.72万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 11.72万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 11.72万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 11.72万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 11.72万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 11.72万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 11.72万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 11.72万 - 项目类别:














{{item.name}}会员




